menu
    • menu
    [{"orgOrder":0,"company":"Biolojic Design","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Antibody-based therapy","moa":"","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Biolojic Design","amount2":0.12,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","amount2New":0.12,"dosageForm":"","sponsorNew":"Biolojic Design \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Biolojic Design \/ Eli Lilly"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"RNA-based Medicines","moa":"","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Mina Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","amount2New":0.02,"dosageForm":"","sponsorNew":"Mina Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Mina Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Ex-vivo Engineered Cell Therapies","moa":"","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Arbor Biotechnologies, Inc","amount2":1.2,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","amount2New":1.2,"dosageForm":"","sponsorNew":"Arbor Biotechnologies, Inc \/ Vertex Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Arbor Biotechnologies, Inc \/ Vertex Pharmaceutical"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Sosei Heptares","amount2":0.72999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","amount2New":0.72999999999999998,"dosageForm":"","sponsorNew":"Sosei Heptares \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Sosei Heptares \/ Eli Lilly"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Dewpoint Therapeutics","amount2":0.75,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","amount2New":0.75,"dosageForm":"","sponsorNew":"Dewpoint Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Dewpoint Therapeutics \/ Novo Nordisk"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dewpoint Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Dewpoint Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Study Phase : Discovery Platform

                            Sponsor : Novo Nordisk

                            Deal Size : $745.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Dewpoint Therapeutics Partners With Novo Nordisk To Explore The Field Of Biomolecular Condensates To Treat Ins...

                            Details : The partnership brings together Novo Nordisk's global leadership in treating diabetes and metabolic diseases with Dewpoint's groundbreaking discovery and AI technology platform to identify modulators of biomolecular condensates.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 22, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Discovery Platform

                            Sponsor : Novo Nordisk

                            Deal Size : $745.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sosei Heptares

                            Japan arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Sosei Heptares

                            Japan arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Study Phase : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $731.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sosei Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diabetes and Metabolic Dise...

                            Details : This new agreement will leverage Sosei Heptares’ StaR® technology and structure-based drug design (SBDD) platform and Lilly’s extensive drug development and commercialization expertise as well as its therapeutic area expertise in diabetes and metabo...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : $37.0 million

                            December 15, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $731.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Arbor Biotechnologies, Inc

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Arbor Biotechnologies, Inc

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ex-vivo Engineered Cell Therapies

                            Therapeutic Area : Endocrinology

                            Study Phase : Discovery Platform

                            Sponsor : Vertex Pharmaceuticals

                            Deal Size : $1,200.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel Ex Vivo Engineered Cell Therapies

                            Details : Under this new partnership, Vertex will receive rights to use Arbor’s technology to research and develop ex vivo engineered cell therapies towards Vertex’s goal of generating fully differentiated, insulin-producing hypoimmune islet cells for the trea...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 24, 2021

                            Lead Product(s) : Ex-vivo Engineered Cell Therapies

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Discovery Platform

                            Sponsor : Vertex Pharmaceuticals

                            Deal Size : $1,200.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Mina Therapeutics

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Mina Therapeutics

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RNA-based Medicines

                            Therapeutic Area : Endocrinology

                            Study Phase : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $15.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            MiNA Therapeutics Announces Equity Investment from Lilly

                            Details : Proceeds from the equity investment will be used to advance and expand MiNA’s internal pipeline of saRNA therapeutics, which is initially focused on immuno-oncology and genetic diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 06, 2021

                            Lead Product(s) : RNA-based Medicines

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $15.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Biolojic Design

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Biolojic Design

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-based therapy

                            Therapeutic Area : Endocrinology

                            Study Phase : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $121.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabe...

                            Details : The research collaboration and license agreement that will leverage Biolojic's AI-based multibody platform to discover and develop a potential novel antibody-based therapy for the treatment of diabetes.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 08, 2021

                            Lead Product(s) : Antibody-based therapy

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $121.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth